Literature DB >> 7501967

Importance of serum CA 125 levels in malignant peritoneal mesothelioma.

H Simsek1, A Kadayifci, E Okan.   

Abstract

Elevated levels of CA 125 have been shown to be present in the serum of patients with ovarian carcinoma, non-gynaecological cancers and some benign diseases. However, the value of CA 125 in malignant peritoneal mesothelioma has not been studied in detail. Therefore, 7 patients with diffuse malignant mesothelioma were included in this study. Median age was 52.4 (range 16-73), and 6 of them were women. The mean serum CA 125 level was 308 kU/l (range 8-1,300 kU/l). Serum CA 125 concentrations were found to be elevated in all 6 female patients. In 3 patients, serum CA 125 levels were followed prospectively and showed a very close correlation with the response to chemotherapy. In 2 responder patients, initially elevated CA 125 levels returned to normal during remission after chemotherapy. In 1 non-responder patient, the serum CA 125 level continued to rise. In conclusion, the serum CA 125 level might be helpful in the diagnosis and follow-up of malignant peritoneal mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 7501967     DOI: 10.1159/000217960

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Authors:  Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

2.  Malignant peritoneal mesothelioma.

Authors:  Stine Munkholm-Larsen; Christopher Q Cao; Tristan D Yan
Journal:  World J Gastrointest Surg       Date:  2009-11-30

3.  CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature.

Authors:  Mahmut Kebapci; Eser Vardareli; Baki Adapinar; Mustafa Acikalin
Journal:  Eur Radiol       Date:  2003-03-25       Impact factor: 5.315

4.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Authors:  Raffit Hassan; Charles Schweizer; Kun F Lu; Barbara Schuler; Alan T Remaley; Susan C Weil; Ira Pastan
Journal:  Lung Cancer       Date:  2009-09-09       Impact factor: 5.705

5.  CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.

Authors:  Nicholas C Nicolaides; Charles Schweizer; Elizabeth B Somers; Wenquan Wang; Shawn Fernando; Erin N Ross; Luigi Grasso; Raffit Hassan; J Bradford Kline
Journal:  Cancer Biol Ther       Date:  2018-04-25       Impact factor: 4.742

6.  Complementary Role of GlcNAc6ST2 and GlcNAc6ST3 in Synthesis of CL40-Reactive Sialylated and Sulfated Glycans in the Mouse Pleural Mesothelium.

Authors:  Yoshiko Takeda-Uchimura; Midori Ikezaki; Tomoya O Akama; Kaho Nishioka; Yoshito Ihara; Fabrice Allain; Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Molecules       Date:  2022-07-16       Impact factor: 4.927

7.  Ca-125: a useful marker to distinguish pulmonary tuberculosis from other pulmonary infections.

Authors:  J Fortún; P Martín-Dávila; R Méndez; A Martínez; F Norman; J Rubi; E Pallares; E Gómez-Mampaso; S Moreno
Journal:  Open Respir Med J       Date:  2009-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.